SurModics Recruits Abbott To Commercialize SurVeil Drug-Coated Balloon

Abbott will pay SurModics $25m upfront and up to $67m in milestones for the exclusive right to commercialization SurVeil worldwide.

Abbott Laboratories Inc. bought exclusive commercialization rights for SurModics Inc.'s SurVeil drug-coated balloon for the superficial femoral artery, as well as options to negotiate agreements for future SurModics' below-the-knee and arteriovenous fistula drug-coated balloon products, the companies announced Feb 27.

Under the terms of the agreement, Surmodics will receive $25m upfront plus up to $67m in various product development milestones....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

More from Device Area